Although anti-TNF-α therapy seems to mitigate the anti-PD-1-related AEs, without interfering with its antitumor effect [54], and PD-1 + TNF-α dual blockade might additionally reduce tumor resistance in vivo [5], combination therapy should be considered with caution. The gene discussed is TNF; the disease is neoplasm.